Visual Outcomes of a New Hydrophobic Trifocal Intraocular Lens in Cataract Treatment: A Prospective Clinical Study.

Purpose: To report the visual outcomes following bilateral implantation of a new trifocal intraocular lens (IOL) in patients with age-related cataracts. Methods: This prospective, noncomparative, multicenter study assessed 126 patients undergoing cataract extraction followed by AT ELANA 841P IOL implantation. At 4-6 months postoperatively, refractive error and predictability, monocular uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), uncorrected intermediate visual acuity (UIVA), distance-corrected intermediate visual acuity (DCIVA), uncorrected near visual acuity (UNVA), distance-corrected near visual acuity (DCNVA), and binocular contrast sensitivity were measured. The binocular defocus curve was evaluated at 3 months postoperatively. Results: Postoperatively, most of the eyes (84.9%) were within ±0.5 D of spherical equivalent (SE) refraction and almost all eyes (98.9%) within ±1.0 D, with a mean SE value of -0.11 ± 0.37 D. Mean monocular CDVA was -0.06 ± 0.08 logMAR and UDVA was -0.01 ± 0.10 logMAR. Mean monocular uncorrected (UIVA and UNVA) and distance-corrected visual acuities (DCIVA and DCNVA) were 0.1 logMAR or better at intermediate (80 cm) and near (40 cm) distances. In the mean defocus curve, a continuous range of 0.1 logMAR or better vision from distance to near was observed. Percentages of eyes achieving CDVA, DCIVA, and DCNVA of 0.1 logMAR or better were 97.2%, 59.1% and 59.1%, respectively. Uncorrected visual acuity of 0.1 logMAR or better was achieved in 88.9% of the eyes at far, 57.1% at intermediate, and 44.4% at near distances. Contrast sensitivity was in the normal range of a phakic population at all spatial frequencies in all light conditions tested, photopic with glare and mesopic with and without glare. Conclusion: Implantation of the new AT ELANA 841P IOL following cataract extraction is safe and effective. Visual acuities at all distances, refractive outcomes, and contrast sensitivity were favorable at 4-6 months postoperatively, providing patients with satisfactory far, intermediate, and near vision. Trial registration: ClinicalTrials.gov identifier: NCT06247683.